Recently, the use of Src inhibitor dasatinib for treating OSCC has been proposed as an attractive strategy via inhibiting Src downstream signaling pathway PI3K/Akt/mTOR and MEK/ERK in HNSCC [75]. The gene discussed is MAP2K7; the disease is head and neck squamous cell carcinoma.